← Research library

Pancragen and pancreatic cell markers in streptozotocin-treated rats

Animal research · 2007

What was studied
28 male Wistar rats, four groups of seven: intact, streptozotocin only, streptozotocin with intramuscular Pancragen, and streptozotocin with oral Pancragen.
Main finding
Insulin-positive pancreatic cell area was 6.43% with injected Pancragen, 5.53% with oral Pancragen and 2.42% with streptozotocin alone. Insulin staining intensity was similar across groups.

Insulin-positive cell area · 6.43 ± 0.35% by injection and 5.53 ± 0.52% by gavage versus 2.42 ± 0.78% with streptozotocin only. · Both active comparisons are reported as p < 0.05 versus streptozotocin only.

Reported findings and study design

28 male Wistar rats, seven per group. The three injury groups received 50 mg/kg streptozotocin intraperitoneally. Two injury groups received 100 µg Pancragen per rat each day for ten days, by intramuscular injection or by gavage. Tissue was collected 20 days after streptozotocin.

Population or model 28 male Wistar rats, four groups of seven: intact, streptozotocin only, streptozotocin with intramuscular Pancragen, and streptozotocin with oral Pancragen.

Results · Dissertation author abstract, streptozotocin model and Fig. 3 narrative, linked to the 2007 journal report
MeasureResultComparison, timing and statistics
Insulin-positive cell area6.43 ± 0.35% by injection and 5.53 ± 0.52% by gavage versus 2.42 ± 0.78% with streptozotocin only.Both active comparisons are reported as p < 0.05 versus streptozotocin only.
Optical density of insulin stainingReported as similar across all four groups.

The dissertation author abstract lists the 2007 paper and gives the detailed schedule and group sizes. These are microscopic outcomes in a rat model.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • The tissue measures are experimental markers in rats. The extractable results do not establish a clinical diabetes effect.
  • The dissertation and paper describe the same experiment. A second 2007 journal report examines glucose and microvascular endpoints in a similar model. Animal reuse across the journal reports is unclear.

Source details

Original journal abstract with dissertation author abstract

Journal abstract and A. P. Ryzhak’s 2008 dissertation author abstract, which lists this paper and reports the model, dosing and tissue outcomes.

Sources checked

Citation

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Animal / experimentalEnglish abstract

I. M. Kvetnoy, A. P. Ryzhak, I. N. Kostyuchek, Y. A. Tafeev. Pancragen and pancreatic cell markers in streptozotocin-treated rats Bulletin of Experimental Biology and Medicine. 143(3):368–371. PMID 18225766.

Study source ↗ · DOI 10.1007/s10517-007-0114-y · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards